

To investigate whether rinsing the bladder with chemotherapy right before an operation that removes the kidney and ureter because of a malignant tumor is effective to reduce the risk of a subsequent bladder tumor

Gepubliceerd: 21-06-2017 Laatste bijgewerkt: 15-05-2024

A preoperative (

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON24959

Bron

Nationaal Trial Register

Verkorte titel

REBACARE

Aandoening

Bladder cancer (blaaskanker), chemotherapy (chemotherapie), nephro-ureterectomy (nephro-ureterectomie), upper urinary tract (hogere urinewegen), urothelial carcinoma (urotheelcelcarcinoom)

Ondersteuning

Primaire sponsor: Erasmus university Medical Center

Overige ondersteuning: IKNL, KWF

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

The bladder cancer recurrence rate up to two years following surgery.

Toelichting onderzoek

Achtergrond van het onderzoek

A prospective, observational, cohort study to investigate the effect of a single, preoperative intravesical instillation with Mitomycin immediately before nephroureterectomy or partial ureterectomy for a urothelial carcinoma of the upper urinary tract on the risk for developing a bladder cancer recurrence compared to a historical control group who received no intravesical instillation.

Doel van het onderzoek

A preoperative (<3 hours) intravesical instillation with Mitomycin will reduce the risk of a metachronous bladder tumor after radical nephroureterectomy or partial ureterectomy for urothelial carcinoma of the upper urinary tract.

Onderzoeksopzet

T0 = screening for eligibility

T1 = inclusion, questionnaires (EQ5D-5L, EORTC QLQ-C30)

T2 = instillation, surgery, CTCAE

T3 = 1 month: postoperative controle and histology, CTCAE

T4 = 3 months: Cystoscopy, urine cytology, quistionnaires (EQ5D-5L, EORTC QLQ-C30)

T5 = 6 months: cystoscopy, urine cytology, CT urography, CT Thorax

T6 = 12 months: cystoscopy, urine cytology, CT urography, CT Thorax

T7 = 18 months: cystoscopy, urine cytology, CT urography

T8 = 24 months: cystoscopy, urine cytology, CT urography

Onderzoeksproduct en/of interventie

Intravesical instillation with Mitomycin within 3 hours before radical nephroureterectomy or partial ureterectomy.

Contactpersonen

Publiek

Thomas van Doeveren
[default]
The Netherlands
06-48795887

Wetenschappelijk

Thomas van Doeveren
[default]
The Netherlands
06-48795887

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- Histologically proven urothelial carcinoma of the upper urinary tract with or without concurrent carcinoma in situ (CIS only is allowed) or patients with a suspicion of a urothelial carcinoma of the UUT on CT-scan plus a urinary cytology sample showing high-grade urothelial carcinoma;
- Patients planned to be treated either by partial ureterectomy or by a radical nephroureterectomy (open or laparoscopic) including a bladder cuff;
- Age $\geq$ 18 years;
- WHO performance status 0, 1 or 2;

- Negative pregnancy test in woman with childbearing potential;
- Written informed consent.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- If pre-operative histology by biopsy shows aberrant histology of the UUT tumor of >50% (adenocarcinoma, small cell carcinoma, squamous cell carcinoma).
- History or presence of a malignant tumor or carcinoma in situ of the bladder.
- History of UUT urothelial carcinoma on the contralateral side or presence of bilateral UUT urothelial carcinoma.
- Known allergy against Mitomycin.
- Anticipated adjuvant intravesical treatment with chemo- or immunotherapy.
- Acute urinary tract infection at the time of inclusion as assessed by urinary culturing.
- Lymphadenopathy or distant metastases as assessed by preoperative CT-scan of thorax and abdomen.
- Any other concurrent severe or uncontrolled disease preventing the safe administration of intravesical Mitomycin.
- Breastfeeding woman.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Anders
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	01-09-2017
Aantal proefpersonen:	170
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies	
Datum:	21-06-2017
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 50424
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL6361
NTR-old	NTR6545
CCMO	NL60919.078.17
OMON	NL-OMON50424

Resultaten